More importantly and consistent with promising results on the clearance of retinal Aβ in an animal model of Age-related Macular Degeneration (AMD) [81], this preclinical study supports the in vivo feasibility of tau-based immunotherapeutic approach—which specifically intercepts the pathologically-relevant species of the protein—as strategy to contrast the eye damage and vision loss occurring in AD development. This evidence concerns the gene MAPT and Alzheimer disease.